ETON

Company Overview — What Does Eton Pharmaceuticals, Inc. Do?

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois. Eton Pharmaceuticals, Inc. (ETON) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Sean E. Brynjelsen and employs approximately 20 people. With a market capitalization of $692M, ETON is one of the notable companies in the Healthcare sector.

Eton Pharmaceuticals, Inc. (ETON) Stock Rating — Hold (April 2026)

As of April 2026, Eton Pharmaceuticals, Inc. receives a Hold rating with a composite score of 38.1/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.ETON ranks #1,252 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Eton Pharmaceuticals, Inc. ranks #95 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ETON Stock Price and 52-Week Range

Eton Pharmaceuticals, Inc. (ETON) currently trades at $26.37. The stock lost $0.73 (2.7%) in the most recent trading session. The 52-week high for ETON is $23.00, which means the stock is currently trading 14.7% from its annual peak. The 52-week low is $11.09, putting the stock 137.9% above its annual trough. Recent trading volume was 400K shares, suggesting relatively thin trading activity.

Is ETON Overvalued or Undervalued? — Valuation Analysis

Eton Pharmaceuticals, Inc. (ETON) carries a value factor score of 37/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 26.14x, versus the sector average of 2.75x. The price-to-sales ratio is 9.91x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, ETON trades at 1351.28x EV/EBITDA, versus 6.34x for the sector.

At current multiples, Eton Pharmaceuticals, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Eton Pharmaceuticals, Inc. Profitability — ROE, Margins, and Quality Score

Eton Pharmaceuticals, Inc. (ETON) earns a quality factor score of 36/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -20.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -5.9% versus the sector average of -33.1%.

On a margin basis, Eton Pharmaceuticals, Inc. reports gross margins of 54.0%, compared to 71.5% for the sector. The operating margin is -2.9% (sector: -66.1%). Net profit margin stands at -6.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 147.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ETON Debt, Balance Sheet, and Financial Health

Eton Pharmaceuticals, Inc. has a debt-to-equity ratio of 252.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.57x, suggesting adequate working capital coverage. Total debt on the balance sheet is $30M. Cash and equivalents stand at $37M.

ETON has a beta of 0.89, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Eton Pharmaceuticals, Inc. is 49/100, reflecting average volatility within the normal range for its sector.

Eton Pharmaceuticals, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Eton Pharmaceuticals, Inc. reported revenue of $69M and earnings per share (EPS) of $-0.17. Net income for the quarter was $-5M. Gross margin was 54.0%. Operating income came in at $-3M.

In FY 2025, Eton Pharmaceuticals, Inc. reported revenue of $80M and earnings per share (EPS) of $-0.17. Net income for the quarter was $-5M. Gross margin was 53.5%. Revenue grew 104.9% year-over-year compared to FY 2024. Operating income came in at $-844,000.

In Q3 2025, Eton Pharmaceuticals, Inc. reported revenue of $22M and earnings per share (EPS) of $-0.07. Net income for the quarter was $-2M. Gross margin was 35.0%. Revenue grew 117.5% year-over-year compared to Q3 2024. Operating income came in at $-1M.

In Q2 2025, Eton Pharmaceuticals, Inc. reported revenue of $19M and earnings per share (EPS) of $-0.10. Net income for the quarter was $-3M. Gross margin was 63.0%. Revenue grew 108.6% year-over-year compared to Q2 2024. Operating income came in at $-1M.

Over the past 8 quarters, Eton Pharmaceuticals, Inc. has demonstrated a growth trajectory, with revenue expanding from $9M to $69M. Investors analyzing ETON stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ETON Dividend Yield and Income Analysis

Eton Pharmaceuticals, Inc. (ETON) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ETON Momentum and Technical Analysis Profile

Eton Pharmaceuticals, Inc. (ETON) has a momentum factor score of 57/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 7/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ETON vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Eton Pharmaceuticals, Inc. (ETON) ranks #95 out of 838 stocks based on the Blank Capital composite score. This places ETON in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ETON against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ETON vs S&P 500 (SPY) comparison to assess how Eton Pharmaceuticals, Inc. stacks up against the broader market across all factor dimensions.

ETON Next Earnings Date

No upcoming earnings date has been announced for Eton Pharmaceuticals, Inc. (ETON) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ETON? — Investment Thesis Summary

Eton Pharmaceuticals, Inc. presents a balanced picture with arguments on both sides. The quality score of 36/100 flags below-average profitability. The value score of 37/100 indicates premium valuation.

In summary, Eton Pharmaceuticals, Inc. (ETON) earns a Hold rating with a composite score of 38.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ETON stock.

Related Resources for ETON Investors

Explore more research and tools: ETON vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ETON head-to-head with peers: ETON vs AZN, ETON vs SLGL, ETON vs VMD.